Observational studyBreast (Edinburgh, Scotland)2026
Pathological complete response and postmastectomy radiation therapy after primary systemic therapy: results from the ReSTORE study.
Observational study in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ReSTORE study aimed to evaluate oncological outcomes and explore the association between pathological complete response (pCR), postmastectomy radiotherapy and nodal irradiation (PMRT), and recurrence.
methodsThis multicentre retrospective study included patients with breast cancer treated with chemotherapy-based primary systemic therapy (PST) followed by skin-or nipple-sparing mastectomy and immediate reconstruction. Locoregional recurrence-free survival (LRRFS) and disease-free survival (DFS) were analysed.
resultsA total of 256 patients were analysed, with a median follow-up of 82 months (range 16-166). In multivariable analysis, node-positive disease at diagnosis was associated with worse LRRFS (HR 8.28, 95% CI 1.06-64.34; p = 0.043). PMRT was associated with a non-significant reduction in locoregional recurrence (HR 0.74, 95% CI 0.29-1.92; p = 0.54). pCR was significantly associated with improved DFS (HR 0.48, 95% CI 0.28-0.82; p = 0.008). Among patients receiving PMRT, those achieving pCR had superior DFS compared with those without pCR (HR 0.23, 95% CI 0.09-0.60; p = 0.002). No significant associations with DFS were observed for age, BRCA status, tumour stage, or receptor status.
conclusionsIn this cohort, pCR and baseline nodal status were key prognostic factors, whereas the true impact of PMRT on outcomes remained uncertain. Nonetheless, our findings do not support omission of PMRT based on pCR alone. Prospective trials and long follow up are required to define response-adapted locoregional treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.